Cargando…

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

PURPOSE: Treatment options for gastroparesis, such as metoclopramide and domperidone, are limited because of safety concerns, which may be exacerbated in the presence of inhibitors of drug metabolism. This study evaluated the effect of itraconazole on the pharmacokinetics, safety, and tolerability o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chunlin, Zhang, Wenwen, Bari, Muhammad, Almansa, Cristina, Baratta, Mike, Rosario, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285519/ https://www.ncbi.nlm.nih.gov/pubmed/34285598 http://dx.doi.org/10.2147/CPAA.S310609

Ejemplares similares

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
por: Kreckler, Laura, et al.
Publicado: (2022)

The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
por: Mukker, Jatinder K., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
por: Whiting, Roger L., et al.
Publicado: (2021)

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants
por: Yamaguchi, Takayoshi, et al.
Publicado: (2021)

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
por: Schneider, F., et al.
Publicado: (2021)

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
por: Changou, Chun A., et al.
Publicado: (2020)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

A randomized clinical trial of vitamin D(3) (cholecalciferol) in ulcerative colitis patients with hypovitaminosis D(3)
por: Mathur, Jagrati, et al.
Publicado: (2017)

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates
por: Haberer, Lynda J., et al.
Publicado: (2013)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

No major effects of vitamin D(3) (1,25 dihydroxyvitamin D(3)) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2016)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
por: Lam, Wing, et al.
Publicado: (2018)

Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin
por: Dutreix, Catherine, et al.
Publicado: (2014)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

A randomized, controlled trial comparing the clinical outcomes of 3D versus 2D laparoscopic hysterectomy
por: Song, Taejong, et al.
Publicado: (2021)

Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3
por: Zhang, Jiazhen, et al.
Publicado: (2017)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

Multivariate Design of 3D Printed Immediate-Release Tablets with Liquid Crystal-Forming Drug—Itraconazole
por: Jamróz, Witold, et al.
Publicado: (2020)

Fantasia in C minor, BWV906 Fifteen two-part inventions ; Fifteen three-part sinfonias (inventions) ; Chromatic fantasia and fugue : in D minor, BWV903 /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application
por: Imoto, Yumi, et al.
Publicado: (2020)

Fluorescent ligands for dopamine D(2)/D(3) receptors
por: Allikalt, Anni, et al.
Publicado: (2020)

Effect of Vitamin D(3) Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double‐Blind Controlled Trial
por: Slobogean, Gerard P., et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D(3) Receptor Antagonists
por: Chen, Jianyong, et al.
Publicado: (2014)

The Effect of Bolus Vitamin D(3) Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR‐pQCT
por: Heyer, Frans L, et al.
Publicado: (2021)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

Prospective Trial of Sacroiliac Joint Fusion Using 3D-Printed Triangular Titanium Implants
por: Patel, Vikas, et al.
Publicado: (2020)

Carpal Tunnel Syndrome: The Role of Occupational Factors Among 906 Workers
por: Ghasemi, Mohammad, et al.
Publicado: (2012)

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
por: Mu, Song, et al.
Publicado: (2021)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
por: Hamberg, Paul, et al.
Publicado: (2011)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Vitamin D3 Is Transformed into 1,25(OH)(2)D(3) by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam
por: Zhu, Hanfei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3lrce54n2js4h3i1phvolo2lv8